An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Trial Profile

An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors SK Life Science
  • Most Recent Events

    • 13 May 2017 This trial has been suspended in Spain.
    • 21 Sep 2016 Planned number of patients changed from 490 to 1200.
    • 21 Sep 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top